匹多莫德口服液对急性加重期慢性阻塞性肺病患者细胞免疫的影响

目的:探讨匹多莫德口服液对慢性阻塞性肺病(COPD)急性发作期患者细胞免疫功能的影响.方法:将COPD急性发作期患者60例分为治疗组和对照组各30例,另选30例体检的健康老年人为正常对照组；对照组给予祛痰、平喘、抗炎、给氧常规治疗,治疗组除常规治疗外给予匹多莫德口服液,每天2次,每次0.4g,疗程14 d,比较两组治疗...

Influence of Pidotimod Oral Liquid on T Lymphocyte Immunological Function of Patients with COPD in Acute Exacerbation Stage

Objective: To study the influences of pidotimod on T lymphocyte immunological function of patients with chronic obstructive pulmonary disease(COPD) in acute stage.Methods: Sixty patients with COPD in acute stage were randomly divided into treatment group(group T) and control group(group C),and thirty healthy people were selected as healthy group(group H).Group C accepted expectorant,anti-asthma,anti-inflammatory and oxygen therapies.Beside of conventional therapy,Group T was given pidotimod oral liquid 0.4 twice a day for 14 days.The clinical effects of the two groups after treatment were compared.Meanwhile,the changes of T cell subgroups were detected before and after treatment.Results: The total effective rate of group T was 96.7% and that of group C was 83.3%,which showed a notable difference between the two groups(P<0.05).The levels of CD+3,CD+4 and CD+4/CD+8 in two diseased groups were significantly lower than those in group H(P<0.01).After treatment,the levels of CD+3,CD+4 and CD+4/CD+8 in group T were obviously higher than those before treatment and those in group C(P<0.05).However,there was no significant difference of the above indexes in group C before and after treatment(P>0.05).Conclusions: Pidotimod could regulate T lymphocyte immunological function of patients with COPD in acute stage and obviously improve their clinical symptoms.